RESVO

Japanese

ABOUT USRESVO Member

Yoshifumi Kobayashi
CEO/Founder
Arata Oh-nishi
CSO/FounderPhD. He found FLC as biomarker and new drug targets. Research Professor of Shimane Univercity
Masatoshi Shimura
CFO
Takayuki Kojima
CTO Ex,Clinical director of Ebora medicine Abigan
Ai sugimoto
Marketing/Founder

WISDOM
&
PRACTICE

VC members

Yusuke Shinozawa
Realtech fund growth manager
Fumiharu Muroga
Realtech fund growth manager

COMPANY

With the power of science, we want to deliver an answer to the patients who are waiting on treatment options, even a day sooner.

This is the message I always try to remember when overseeing the RESVO business. I had a friend who suffered from neurodevelopmental disorders, which drove me to found RESVO with Arata who was my research teammate in the research institution at that time.
“Thinking will come true.” This is our principles and the words that I exchanged with him when founding my company.
We’ve been working through collaborations in and outside of the company to make the thinking come true and identify solutions for neurodevelopmental disorders with our technologies. We are dedicated to the discovery of the treatment options for the patients and their families of neurodevelopmental disorders and other diseases which do not have established treatment strategies, and the healthcare professionals who tirelessly support them.

Company
RESVO, INC.
CEO
Yoshifumi Kobayashi
Establishment
January 23 2015
Head Office
7-1-204, Haneda Asahi-cho,Ota-ku,Tokyo
Capital
58.18 million yen(Capital reserve not included)
Business content
  • R&D on mental illness and Stress related. Joint research and contract inspection business in the above areas.
CONTACT

Contact

Please visit our contact page for potential research partnering and collaborating.

Contact Us